Who is sponsoring NCT05016518?

NCT05016518 is sponsored by Gangnam Severance Hospital.

What drugs are being tested in NCT05016518?

Interventions in NCT05016518: Arm I (Propofol group), Arm II (Remimazolam group).

What condition does NCT05016518 study?

NCT05016518 studies Patients Undergoing Thyroid Surgery for Neoplasm.

Is NCT05016518 still recruiting?

NCT05016518 is currently completed. Last updated 1 June 2022.

Last reviewed 2022-06-01 · How we verify

NCT05016518

Name: Drug Landscape Pharmaceutical Database
Creator: Drug Landscape
Published: 2026-01-01
License: https://creativecommons.org/licenses/by/4.0/

Comparison of Quality of Recovery (QoR)-15 Scores Between Propofol and Remimazolam Anesthesia

Completed NA Last updated 1 June 2022

What this trial tests

NA trial testing Arm I (Propofol group) in Patients Undergoing Thyroid Surgery for Neoplasm in 140 participants. Completed in 20 May 2022.

Timeline

16 September 2021

Primary endpoint
18 May 2022

20 May 2022

Quick facts

Lead sponsor	Gangnam Severance Hospital
Phase	NA
Status	Completed
Study type	INTERVENTIONAL
Allocation	randomized
Design	parallel
Masking	triple
Primary purpose	treatment
Enrollment	140
Start date	16 September 2021
Primary completion	18 May 2022
Estimated completion	20 May 2022
Sites	1 location across South Korea

Drugs / interventions tested

Arm I (Propofol group)
Arm II (Remimazolam group)

Conditions studied

Patients Undergoing Thyroid Surgery for Neoplasm — all drugs for Patients Undergoing Thyroid Surgery for Neoplasm →

Sponsor

Gangnam Severance Hospital

Who can join

Adults 20 to 65, female only, with Patients Undergoing Thyroid Surgery for Neoplasm. Patients with the condition only — healthy volunteers not accepted.

Sponsor's own description

Remimazolam is a ultra-short-acting benzodiazepine that is rapidly metabolized in the body by tissue esterase and not accumulates in the body for long periods of infusion. In addition, similar to other benzodiazepines, it is possible to reverse the sedation and anesthetic effects through flumazenil. It has no injection pain and infusion syndrome compared with propofol. There is no study to investigate overall postoperative functional recovery via QoR-15 in patients receiving TIVA using remimazolam. The purpose of this study is to determine whether there is any difference in the quality of postoperative recovery between propofol-based and remimazolam-based total intravenous anesthesia in female patients undergoing thyroidectomy. The QoR-15 questionnaire score, pain, nausea/vomiting, and the frequency of complications are evaluated and compared between the two groups.

Publications & conference data

1 peer-reviewed publication reference this trial (live from Europe PMC):

Comparison of the recovery quality between remimazolam and propofol after general anesthesia: systematic review and a meta-analysis of randomized controlled trials.
Zhu C, Xie R, Qin F, Wang N, et al · · 2024 · cited 2× · PMID 39210920 · DOI 10.7717/peerj.17930

Verify or expand the search:

Other Gangnam Severance Hospital trials

Trials by the same sponsor.

NCT07505628 — AI-based Rehabilitation for Hip and Knee Surgery Patients · NA · not yet recruiting
NCT07311122 — Endocrine Therapy Base on 21-gene RS · not yet recruiting
NCT07011823 — Immune-checkpoint Blockade After Partial Breast Irradiation by Pembrolizumab in Early TNBC · Phase 2 · not yet recruiting
NCT07211451 — Axillary Nodal Burden in HER2+ and TNBC · completed
NCT06839716 — Comparison of Ropivacaine-Poloxamer 407 Hydrogel and TAP Block for Postoperative Pain Management in Laparoscopic/Robotic · NA · recruiting

Verify against primary sources

ClinicalTrials.gov — authoritative US registry record
WHO ICTRP — international registry index
EU Clinical Trials Register
Sponsor press releases (Google)

Data sources for this page

Trial protocol + status: ClinicalTrials.gov NCT05016518 (US National Library of Medicine, public domain)
Publications: Europe PMC API search by NCT ID, retrieved 10 June 2026
Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
Sponsor: as reported to ClinicalTrials.gov by Gangnam Severance Hospital
Last refreshed: 1 June 2022

Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT05016518.

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing